Evidence map›Paper›PMID 26658107›Full record

ArticlePloS one2015

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.

Kana Hasegawa, Satomi Tanaka, Fumihiro Fujiki, Soyoko Morimoto, Hiroko Nakajima, Naoya Tatsumi, Jun Nakata, Satoshi Takashima, Sumiyuki Nishida, Akihiro Tsuboi and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Immune evasion by cancer stem cells.Regenerative therapy · 2021
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Kana HasegawaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Satomi TanakaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Fumihiro FujikiDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Soyoko MorimotoDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Hiroko NakajimaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Naoya TatsumiDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Jun NakataDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Satoshi TakashimaDepartment of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Sumiyuki NishidaDepartment of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Akihiro TsuboiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yoshihiro OkaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yusuke OjiDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Haruo SugiyamaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Naoki HosenDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Osaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia differs substantially with respect to stromal milieu from tumors that progress locally as solid masses, and the physiological importance of immunosurveillance in leukemia remains unclear. However, currently available mouse leukemia models have critical limitations in the context of analyzing immunological regulation of leukemia development. In this study, we transferred mouse MLL/AF9 leukemia-initiating cells into immunocompetent recipient mice without any pre-conditioning such as irradiation, and then analyzed the spontaneous T cell response to an immunogenic antigen expressed in leukemia cells. When the minimum numbers of leukemia-initiating cells for engraftment were transferred, leukemia cells were eradicated by the adaptive immune response in most, if not all, wild-type mice, but not in Rag2-/- recipient mice, which lack adaptive immunity. By contrast, mice transplanted with larger numbers of leukemia cells always developed leukemia. In mice with advanced leukemia, antigen-specific CTLs were also expanded, but were unresponsive to antigen stimulation and expressed high levels of PD-1 and LAG-3. These results provide the first clear demonstration that the spontaneous CTL response to a tumor-cell antigen has the potential to eradicate leukemia, whereas antigen-specific CTLs are exhausted in animals with advanced leukemia. This immunocompetent mouse leukemia model provides a useful platform for developing effective immunotherapies against leukemia.

Indexed as

ImmunocompetenceAdaptive ImmunityAnimalsAntigens, NeoplasmCell Line, TumorDisease Models, AnimalDisease ProgressionFemaleLeukemiaMice, Inbred C57BLMice, TransgenicMyeloid-Lymphoid Leukemia ProteinT-Lymphocytes, CytotoxicAntigens, NeoplasmMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID26658107
PMCPMC4684241
OpenAlexW2192979940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.